PEAK6’s Arcus Biosciences RCUS Stock Holding History

PEAK6’s Portfolio RCUS Stock Details RCUS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-10,000	Closed	-$81.4K	–	3378
2025 Q2	$81.4K	Hold	10,000	–	–	﹤0.01%	2646
2025 Q1	$78.5K	Hold	10,000	–	–	﹤0.01%	2636
2024 Q4	$149K	Buy	+10,000	New	+$163K	﹤0.01%	2632

Other funds holding RCUS

Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

PEAK6's RCUS Position: Q3 2025 in Review

PEAK6 sold out of Arcus Biosciences (RCUS) in Q3 2025, closing a stake of 10,000 shares — an estimated $81.4K sold.

PEAK6 first reported a position in RCUS in Q4 2024 and held it in 3 quarters. The position peaked at $149K in Q4 2024. 190 funds tracked by Wall St. Rank hold RCUS as of Q3 2025.

PEAK6 reported no remaining Arcus Biosciences position as of Q3 2025 after selling out during the quarter.
PEAK6 sold 10,000 Arcus Biosciences shares in Q3 2025, an estimated $81.4K.
PEAK6 first reported a position in Arcus Biosciences in Q4 2024 and held it in 3 quarters.
PEAK6's Arcus Biosciences position peaked at $149K in Q4 2024.
190 funds tracked by Wall St. Rank held Arcus Biosciences as of Q3 2025.

Based on PEAK6's 13F filing for Q3 2025, filed 14 Nov 2025.